RNA interference therapy: a new solution for intracranial atherosclerosis?

Area of Science:

• Neurology
• Cardiovascular Research
• Biomedical Imaging

Background:

• Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke globally.
• ICAS patients face a higher risk of recurrent stroke, even with medical treatment.
• Plaque characteristics, not just luminal stenosis, are linked to stroke risk.

Purpose of the Study:

• To investigate the association between intraplaque hemorrhage (IPH) in middle cerebral artery (MCA) stenosis and ischemic stroke.
• To explore novel therapeutic strategies targeting plaque stabilization in ICAS.
• To evaluate the potential of RNA interference (RNAi) therapy delivered by nanoparticles for imaging and treatment.

Main Methods:

• Utilized high-resolution magnetic resonance imaging (HRMRI) to assess MCA plaque morphology and components.
• Identified high signal on T1-weighted fat-suppressed images (HST1) as an indicator of IPH.
• Proposed RNA interference (RNAi) therapy combined with modified nanoparticles for targeted intervention.

Main Results:

• HRMRI revealed that HST1, indicative of IPH, is associated with ipsilateral brain infarction in MCA stenosis patients.
• Symptomatic MCA stenosis patients exhibit a higher prevalence of IPH and neovasculature.
• Nanoparticle-delivered RNAi therapy is hypothesized for in vivo imaging and targeted treatment.

Conclusions:

• Intraplaque hemorrhage in MCA stenosis is a significant marker for ischemic stroke risk.
• Targeting IPH and neovasculature presents a promising strategy for plaque stabilization in ICAS.
• Nanotechnology offers potential for advanced diagnostics and therapeutics in atherosclerosis treatment.